[
  {
    "ts": "2026-02-05T02:35:01+00:00",
    "headline": "Pfizer Inc. (PFE): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Pfizer Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $25.86 as of January 28th. PFE’s trailing and forward P/E were 15.41 and 9.14, respectively according to Yahoo Finance. Pfizer Inc. discovers, develops, manufactures, markets, […]",
    "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-bull-case-023501864.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "7aaf0102-d52e-3849-9dee-db6053190875",
      "content": {
        "id": "7aaf0102-d52e-3849-9dee-db6053190875",
        "contentType": "STORY",
        "title": "Pfizer Inc. (PFE): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Pfizer Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $25.86 as of January 28th. PFE’s trailing and forward P/E were 15.41 and 9.14, respectively according to Yahoo Finance. Pfizer Inc. discovers, develops, manufactures, markets, […]",
        "pubDate": "2026-02-05T02:35:01Z",
        "displayTime": "2026-02-05T02:35:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/a06794712cff4e68063daa19ac3bfca9",
          "originalWidth": 1280,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nzjYheBryIX.ZHx_P61Kpg--~B/aD03Njg7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/a06794712cff4e68063daa19ac3bfca9.cf.webp",
              "width": 1280,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uDT3MYZ6ZZz38EGpyNCa9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a06794712cff4e68063daa19ac3bfca9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-bull-case-023501864.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-bull-case-023501864.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-05T09:16:23+00:00",
    "headline": "Pfizer’s Obesity Bet PF-3944 Advances As Shares Screen Undervalued",
    "summary": "Pfizer (NYSE:PFE) reported positive topline Phase 2b results for its once monthly GLP-1 obesity candidate PF-3944. The drug, acquired through Pfizer's purchase of Metsera, showed significant weight loss with a safety profile the company describes as favorable. Pfizer plans to launch an extensive Phase 3 program in 2026, with more than 10 trials focused on PF-3944 in obesity. For you as an investor, this development puts Pfizer directly into the center of the fast growing obesity drug...",
    "url": "https://finance.yahoo.com/news/pfizer-obesity-bet-pf-3944-091623987.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e1c0a3e7-f819-3572-b663-6af7d8e79331",
      "content": {
        "id": "e1c0a3e7-f819-3572-b663-6af7d8e79331",
        "contentType": "STORY",
        "title": "Pfizer’s Obesity Bet PF-3944 Advances As Shares Screen Undervalued",
        "description": "",
        "summary": "Pfizer (NYSE:PFE) reported positive topline Phase 2b results for its once monthly GLP-1 obesity candidate PF-3944. The drug, acquired through Pfizer's purchase of Metsera, showed significant weight loss with a safety profile the company describes as favorable. Pfizer plans to launch an extensive Phase 3 program in 2026, with more than 10 trials focused on PF-3944 in obesity. For you as an investor, this development puts Pfizer directly into the center of the fast growing obesity drug...",
        "pubDate": "2026-02-05T09:16:23Z",
        "displayTime": "2026-02-05T09:16:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-obesity-bet-pf-3944-091623987.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-obesity-bet-pf-3944-091623987.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-05T09:05:00+00:00",
    "headline": "Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?",
    "summary": "Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.",
    "url": "https://www.fool.com/investing/2026/02/05/can-pfizer-crash-the-lilly-and-novo-nordisk-weight/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "5c75ef06-3987-32bc-a8c6-8660442c1dfd",
      "content": {
        "id": "5c75ef06-3987-32bc-a8c6-8660442c1dfd",
        "contentType": "STORY",
        "title": "Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?",
        "description": "",
        "summary": "Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.",
        "pubDate": "2026-02-05T09:05:00Z",
        "displayTime": "2026-02-05T09:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/6a9cd55787a1959dc1ae5736f6015ba3",
          "originalWidth": 1024,
          "originalHeight": 652,
          "caption": "Pfizer name and logo on glass.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ou0vmboVTY4v6hAwUyQKDA--~B/aD02NTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/6a9cd55787a1959dc1ae5736f6015ba3.cf.webp",
              "width": 1024,
              "height": 652,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pIHRcKLCwjnZWY4iY2UXnQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/6a9cd55787a1959dc1ae5736f6015ba3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/05/can-pfizer-crash-the-lilly-and-novo-nordisk-weight/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-crash-lilly-novo-nordisk-090500888.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-05T09:00:00+00:00",
    "headline": "BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration",
    "summary": "BioPhorum, the pharmaceutical industry's most trusted collaborative network for change, today announces the formation of its inaugural Strategic Advisory Board.",
    "url": "https://finance.yahoo.com/news/biophorum-announces-formation-strategic-advisory-090000803.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "b74b8036-e57b-3086-a16f-7d4fbc4303f0",
      "content": {
        "id": "b74b8036-e57b-3086-a16f-7d4fbc4303f0",
        "contentType": "STORY",
        "title": "BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration",
        "description": "",
        "summary": "BioPhorum, the pharmaceutical industry's most trusted collaborative network for change, today announces the formation of its inaugural Strategic Advisory Board.",
        "pubDate": "2026-02-05T09:00:00Z",
        "displayTime": "2026-02-05T09:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/dbfe71d9e524f3517a76456543af8b32",
          "originalWidth": 400,
          "originalHeight": 154,
          "caption": "The biopharmaceutical industry’s most trusted collaborative network for change.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YQ5a592cBQAVu47wcmBSyA--~B/aD0xNTQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/dbfe71d9e524f3517a76456543af8b32.cf.webp",
              "width": 400,
              "height": 154,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.WcqSIj7bTMRoMOWaeVblw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/dbfe71d9e524f3517a76456543af8b32.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biophorum-announces-formation-strategic-advisory-090000803.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biophorum-announces-formation-strategic-advisory-090000803.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SARTF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]